A Positive Trial

Genentech's Lucentis helps prevent vision loss due to diabetic macular edema, a phase three clinical trial sponsored by the National Eye Institute found. The trial, which included 691 patients or 854 eyes (as not everyone had both eyes treated), found that 3 to 4 percent of Lucentis-treated eyes had visual loss after the one year while 13 percent of those treated with lasers did, reports the New York Times.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.